Essential medicines and health products

Good Governance for Medicines (GGM)

The Good Governance for Medicines approach is to support policy-makers and national officials to understand where the strengths and weaknesses lie in the national pharmaceutical systems in order to develop and apply appropriate interventions. The programme has now been implemented in 36 countries worldwide.

The need for good governance in the pharmaceutical sector

Increasing access to medicines remains one of the major global challenges to achieve Universal health Coverage. In recent years governance has been identified as being crucial for universal access and sector performance, for example through increasing efficiency and reducing wastage. Good governance has been identified as a priority area of work in the WHO Medicines Strategy 2008-2013.

Medicines Transparency Alliance

Good governance and the critical need for evidence on effective interventions to increase access to medicines has been identified as a priority area of work by the WHO Medicines Strategy 2008-2013. Efforts of the Department for Essential Medicines and Health Products to improve good governance in the pharmaceutical sector, through policy and regulatory support initiatives and programmes such as the Medicines Transparency Alliance and Good Governance for Medicines, have generated considerable insight into understanding how good governance can impact on the availability and affordability of quality medicines.


WHO collaborates with many different stakeholders to improve governance in the pharmaceutical sector.



  • WHO technical working group on good governance in pharmaceutical systems, Geneva - December 2017

    As part of the revision process of the assessment tool for measuring transparency in the public pharmaceutical system a revised draft was field tested in 5 sites Assessors involved in the field test were invited to a meeting to share experiences with the revised tool with the aim of finalizing the pharmaceutical system transparency and accountability assessment tool and to review experiences with translating the results into actions.

  • Bi-Regional Consultation on Good Governance for Improved Access to Medicines, Manila, Philippines, November 2015

    A bi-regional GGM consultation between the WHO Western Pacific Region and WHO South East Asian Region was held in Manila in November 2015 to review and share effective governance practices and strategies for improving access to medicines and to address the implementation of Resolution WHA67.22. Participants included ministries of health, regulatory authorities, development partners, civil society, and pharmacists. The report summarizes the discussion and recommendations of the participants.

  • Medicines Transparency Alliance Global Meeting, Switzerland, December 2014

    Representatives from participating countries from the public and private sectors, civil society and WHO shared experiences in improving access to quality essential medicines through improved transparency in the pharmaceutical sector.

  • GGM technical working group meeting, Tunis, March 2014

    The GGM technical working group met in Tunis in March 2014 to discuss the development of guidance documents for the GGM programme. The report summarizes the discussions and recommendations of the participants.

Good Governance for Medicines Model Framework

World Health Assembly 66 Side Event
20 May 2013

The findings and the recommendations from the evaluation of the Good Governance for Medicines Programme was presented. The experiences from Thailand and Malawi was also shared in a event held at this year World Health Assembly in Geneva.


Dr. Gilles Forte
Policy, Access and Use
Department of Essential Medicines and Health Products